Background: Arsenic exposure through drinking water persists in many regions. Inorganic As (InAs) is methylated to monomethylarsenical species (MMAs) and dimethyl-arsenical species (DMAs), facilitating urinary excretion. Arsenic methylation is dependent on one-carbon metabolism, which is influenced by nutritional factors such as folate and creatine. Objective: This study investigated the effects of folic acid (FA) and/or creatine supplementation on the proportion of As metabolites in urine. Design: In a 24-wk randomized, double-blinded, placebo-controlled trial, 622 participants were assigned to receive FA (400 or 800 μg per day), 3 g creatine per day, 400 μg FA + 3 g creatine per day, or placebo. The majority of participants were folate sufficient; all received As-removal water filters. From wk 12-24, half of the participants receiving FA received placebo. Results: Among groups receiving FA, the mean decrease in ln(%InAs) and %MMAs and increase in %DMAs exceeded those of the placebo group at wk 6 and 12 (P < 0.05). In the creatine group, the mean decrease in %MMAs exceeded that of the placebo group at wk 6 and 12 (P < 0.05); creatine supplementation did not affect change in %InAs or %DMAs. The decrease in %MMAs at wk 6 and 12 was larger in the 800 µg FA than in the 400 µg FA group (P = 0.034). There were no differences in treatment effects between the 400 µg FA and creatine + FA groups. Data suggest a rebound in As metabolite proportions after FA cessation; at wk 24, log(%InAs) and %DMAs were not significantly different than baseline levels among participants who discontinued FA supplementation.
INTRODUCTION
Chronic arsenic exposure is a major global public health issue (1) . In Bangladesh, roughly 57 million people are exposed to concentrations in drinking water exceeding the WHO's guideline of 10 μg/L (2, 3). Chronic As exposure is associated with a range of health outcomes including skin lesions, skin and internal cancers, neurologic impairment, cardiovascular and pulmonary diseases, and endocrine disruption (1) .
Ingested inorganic As (InAs) undergoes a series of stepwise biotransformation reactions in which it is methylated by arsenic methyltransferase (AS3MT) (4) using the methyl donor S-adenosylmethionine (SAM) to form monomethylarsonic acid (MMAs V ) and dimethylarsinic acid (DMAs V ) (Figure 1 ) (5). Variation in As methylation capacity between populations and individuals may modify the association between As exposure and Arsenate FIGURE 1 Arsenic methylation. Ingested inorganic As (InAs) undergoes a series of stepwise biotransformation reactions. Arsenite (As III ) is actively methylated by arsenic methyltransferase (AS3MT) using the methyl donor S-adenosylmethionine (SAM) to form monomethylarsonic acid (MMAs V ). MMAs V is reduced to monomethylarsonous acid (MMAs III ), and MMAs III is methylated to form dimethylarsinic acid (DMAs V ). GSH, reduced glutathione; GSSG, oxidized glutathione. health outcomes (6) . Complete methylation of As to DMAs V is important as toxicologic studies have demonstrated that MMAs III is the most toxic As species (7, 8) . Although the relative toxicity of MMAs III and MMAs V is difficult to assess in human studies because MMAs III is rapidly oxidized to MMAs V , a higher proportion of urinary MMAs (III+V) has been associated with higher risk of arsenic-induced skin lesions (9) (10) (11) , peripheral vascular disease, skin and bladder cancers, and atherosclerosis, as reviewed by Steinmaus et al. (12) .
Arsenic methylation is dependent on one-carbon metabolism for SAM synthesis (13) . In this pathway, the one-carbon unit carried by 5-methyl-tetrahydrofolate (5-MTHF) is transferred to homocysteine to form methionine, which is activated to form SAM. Dietary creatine may also affect As metabolism. Endogenous biosynthesis of creatine consumes an estimated 40% of SAM (14) . Dietary creatine consumption from animal sources downregulates endogenous creatine biosynthesis, reducing the loss of methyl groups incurred by creatine biosynthesis. Among omnivores, approximately half of the body's supply of creatine is provided by food (14) .
We have examined the role of folate nutritional status on As methylation in several prior studies (15) (16) (17) . The effects of supplementation with 400 μg folic acid (FA) per day, the US recommended daily allowance (RDA), among Bangladeshi adults with low plasma folate (<9 nmol/L) were tested in a randomized controlled trial (RCT). After 12 wk, the treatment group had a significantly larger increase in the percentage of urinary dimethyl-arsenical species (%DMAs) and decreases in urinary ln(%InAs), the percentage of urinary monomethyl-arsenical species (%MMAs) (16) , total blood As, and blood MMAs (17) as compared with the placebo group. Changes in total blood As in the RCT we present here have been previously published . Among As-exposed Bangladeshi adults selected independent of folate status, a larger decrease in ln(blood As) was observed in the treatment group receiving 800 μg FA per day for 12 wk relative to the placebo group. Urinary creatinine, a catabolite of creatine, has also been negatively associated with urinary %InAs and positively associated with urinary %DMAs (15, (21) (22) (23) (24) .
It is not known if FA supplementation increases As methylation in a population of mixed folate-deficient and -sufficient individuals, which may have important policy implications. The current RCT investigated the effects of 400 μg/d and 800 μg/d FA supplementation on urinary As metabolites among the general population of As-exposed adults in Araihazar, Bangladesh. We also tested the effect of reducing methylation demand through creatine supplementation on As methylation.
METHODS

Subjects
The Folic Acid and Creatine Trial (FACT) is an RCT that has been previously described (20) . Briefly, FACT participants were recruited from the Health Effects of Arsenic Longitudinal Study (HEALS), a prospective cohort study of >30,000 adults living in Araihazar, Bangladesh that was initiated in 2000 (25) . HEALS participants were married, residing in the study area for ≥5 y, and drinking from their household well for ≥3 y. FACT participants were randomly selected from the HEALS cohort and were eligible if they were drinking for ≥1 y from a household well that had an As concentration ≥50 μg/L. Exclusion criteria were pregnancy, taking nutritional supplements, having proteinuria, renal disease, diabetes, gastrointestinal problems, or other health problems.
Study design
The study design has been described in detail by Peters et al. (20) . A total of 622 participants were recruited (Supplemental Figure 1 : Consolidated Standards of Reporting Trials (CON-SORT) Flow Diagram). The sample size was selected to achieve 80% power at alpha = 0.05 to detect a moderate effect size in the mean differences in change in total blood As concentrations or percentage urinary As metabolites between 2 treatment groups (i.e., 0.45 SD) and assuming some participants might not complete the study. Participants were randomly assigned to 1 of 5 treatment groups: placebo (n = 104), 400 μg FA per day (referred to as 400FA; n = 156), 800 μg FA per day (800FA; n = 154), 3 g creatine per day (creatine; n = 104), and 3 g creatine and 400 μg FA per day (creatine + 400FA; n = 104). To ensure an equal number of men and women in each treatment group and balance between treatment groups, men and women were randomized separately and in blocks, and assigned to treatment groups in the ratio 1 (placebo):1.5 (400FA):1.5 (800FA):1 (creatine):1 (creatine + 400FA). The order of treatment assignments within the blocks was determined by a random permutation generated by a statistician at Columbia University. One data management specialist in the United States and 1 in Bangladesh assigned letters to treatment groups (i.e., A, B, C, D, E). The creatine dose of 3 g/d was selected to overcompensate for daily creatine loss, approximately 1.9 g for a 20-39-y-old 70-kg male, and thus to be sufficient to downregulate endogenous creatine synthesis (14) . All supplements were obtained from Atrium Innovations, Inc. (Westmount, Quebec). Field staff received barcode-labeled pill bottles from a pharmacist and distributed bottles in order of the random treatment assignment. With the exception of the data management specialists who assigned treatment groups, all participants, field staff, village health workers, laboratory technicians, and investigators were blinded to the treatment for the duration of the study.
The study consisted of two 12-wk phases (Figure 2) . During the first phase, participants received daily supplements or placebo according to their treatment group assignment. The primary outcome of interest (previously published) was total blood As (20) . For the current analyses, data from the first phase of the study were employed to evaluate our a priori secondary outcomes, i.e., the effects of FA and/or creatine supplementation on As methylation capacity. During the second phase of the study, participants in the 400FA and 800FA groups were randomly assigned to continue FA supplementation (400 μg FA per day, referred to as 400FA/FA: n = 77; 800 μg FA per day, 800FA/FA: n = 77) or receive placebo (400FA/placebo: n = 76; 800FA/placebo: n = 74) for the duration of the trial (wk [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Participants in the creatine and creatine + 400FA groups were also given placebo during the second phase in order to maintain the study blind. Data from the second phase of the study were used to determine if a rebound in urinary As metabolites occurred after FA supplementation was discontinued.
Ethics
The study protocol was approved by the Columbia University Medical Center Institutional Review Board and the Bangladesh Medical Research Council. Staff physicians in Bangladesh obtained informed consent from participants.
Fieldwork
Five trained teams, each consisting of 1 interviewer and 1 physician, recruited participants and performed all follow-up home visits during which biological samples were collected. Venous blood samples were collected at baseline, wk 12, and wk 24. Urine samples were collected at baseline and wk 1, 6, 12, 13, 18, and 24. Study recruitment and follow-up were conducted from December 2009 through May 2011.
All participants received READ-F As removal filters (READ-F filter; Brota Services International, Bangladesh) and were repeatedly encouraged to use them for all drinking and cooking water throughout the study (26) . During the first phase, all participants received 2 pill bottles: 1 containing FA pills or matched placebo pills, and 1 containing creatine pills or matched placebo pills. During the second phase, all participants received 1 pill bottle containing FA pills or matched placebo pills. Village health workers performed daily home visits, during which they observed participants take the pills or inquired about compliance. At the end of each study phase, pill bottles were collected and pill counts were performed. Compliance ranged from 79.1% to 100% (median: 99.5%; IQR: 98.3%, 100.0%) and did not differ substantially between treatment groups or study phases (20) .
Twelve participants were dropped from the study owing to adverse events (n = 6; placebo group: abdominal cramps; 400FA group: hypertension; 800FA group: abdominal cramps, severe vertigo, bilateral hydronephrosis; creatine group: severe vertigo), pregnancy (n = 3; 400FA, creatine, and creatine + 400FA groups), missing baseline blood sample (n = 1; creatine group), and dropout (n = 2; placebo and 400FA groups). The remaining sample consisted of 610 participants (placebo: n = 102; 400FA: n = 153; 800FA: n = 151; creatine: n = 101; creatine + 400FA: n = 103) (Supplemental Figure 1) .
Sample handling
Venous blood was collected in vacutainer tubes containing EDTA. Blood samples were stored in IsoRack cool packs (Brinkmann Instruments, Riverview, FL) at 0°C. Within 4 h, samples were transported to the field clinic in Araihazar. Plasma was separated from venous blood by centrifugation at 3000 × g for 10 min at 4°C. Whole blood and plasma samples were stored at −80°C and shipped on dry ice to Columbia University for analysis. Urine was collected in 50-mL acid-washed polypropylene tubes, stored in portable coolers for transport to the field clinic within 4 h, frozen at −20°C, and shipped to Columbia University on dry ice.
Water arsenic
To assess baseline As exposure, unfiltered water samples from the tube wells used by study participants were collected. Samples were collected in 20-mL polyethylene scintillation vials, acidified to 1% with the use of high-purity Optima HCl (Fisher Scientific) for ≥48 h, diluted 1:10, and analyzed via high-resolution inductively coupled plasma mass spectrometry (ICP-MS) with germanium spike to correct for fluctuations in sensitivity. To monitor As removal by the filters, filtered water was tested in the field with Hach EZ Arsenic test kits; approximately 50 filters were replaced during the study (26) .
Laboratory measures
Laboratory methods have been described in detail by Peters et al. (20) . Briefly, total blood As in whole blood was assessed through the use of a PerkinElmer Elan DRC II ICP-MS (Waltham, MA) with an AS 93+ autosampler (intra-and interassay CVs: 2.7% and 5.7%, respectively). Plasma folate and B-12 were assessed via radioimmunoassay (SimulTRAC-SNB; MP Biomedicals, Santa Ana, CA) (plasma folate intra-and interassay CVs: 5% and 13%, respectively; B-12 intra-and interassay CVs: 6% and 17%, respectively). Plasma total homocysteine was measured with high-performance liquid chromatography (HPLC) with fluorescence detection (intra-and interassay CVs: 5% and 7%, respectively).
Urinary As metabolites were measured via HPLC separation of arsenobetaine, arsenocholine, As III , As V , MMAs (MMAs III + MMAs V ), and DMAs, and detection by ICP-MS with a dynamic reaction cell as described by Reuter et al. (27) (intra-and interassay CVs for arsenobetaine + arsenocholine: 10.1% and 12.2%; As III + As V : 2.7%, 4.7%; MMAs: 2.8%, 3.9%; DMAs: 0.6% and 1.3%, respectively). As III can oxidize to As V during sample storage and analysis, and therefore total InAs (As III + As V ) is reported. Specific gravity (SG) was measured by refractometer.
Study sample
Six follow-up urine samples were missing, and 18 urine samples with missing SG were removed from the dataset. We suspect that some participants may have added water to urine collection cups in an effort to increase fluid volume. Therefore, urine samples with SG ≤ 1.001, outside the normal range (28), were removed from the dataset (n = 620 out of 4239 samples). Samples with %InAs ≥ 55 were also considered to be outside of normal values (29) and removed (n = 22 out of 3619 samples); participants without a baseline urine sample (n = 50) or without the majority of urine samples (i.e., ≥4 time points) (n = 17) were also removed. One participant with baseline SG of 1.002, but biologically implausibly high total urinary As, was also removed. A total of 542 participants were included in analyses (placebo: n = 90; 400FA: n = 133; 800FA: n = 129; creatine: n = 94; creatine + 400FA: n = 96) (Supplemental Figure 1) . With the exception of urine As metabolites, baseline characteristics did not differ significantly between participants included and excluded from analyses.
The concentrations of urinary As metabolites were adjusted for between-individual differences in urine dilution at each time point by multiplying the sample concentration by the ratio (mean SG -1)/(subject's SG -1) (30). Arsenobetaine and arsenocholine are nontoxic dietary sources of As (31) and were therefore excluded from analyses. Seven samples had urinary As III concentrations below the limit of detection (LOD). These samples were replaced with values of LOD/2. The proportions of each As metabolite in urine were calculated by dividing the concentration of each species by the concentration of total urinary As (As III + As V + MMAs + DMAs).
Statistical analysis
An intent-to-treat approach was used in all analyses. Summary statistics for baseline characteristics by treatment group were calculated. Overall differences between treatment groups at baseline were detected through the use of the Kruskall-Wallis test for continuous variables and the chi-square test for categoric variables. One-factor ANOVA was used to detect treatment group differences in urinary As metabolites and nutritional factors at baseline and follow-up, where %InAs, red blood cell (RBC) folate, plasma folate, and homocysteine were log transformed to meet model assumptions. To compare each of the 4 treatment groups with the placebo group, Dunnett's t test with multiple comparisons was used to control the Type I experiment-wise error rate for each As metabolite variable.
Linear models with repeated measures were applied to the outcomes of percentage urinary As metabolites measured over time to examine treatment effects during the first phase. Percentage InAs was log transformed to improve model fitting and reduce the impact of extreme values. Models included predictors of time, treatment group, and group-by-time interactions. The interaction parameters indicate treatment group differences in mean withinperson change since baseline. A generalized estimating equation approach was used to estimate model parameters and test hypotheses with the use of all available data and accounting for within-subject correlations in the repeated measures. The Wald test was used to detect differences in the within-person change in As metabolite proportions between each treatment group and the placebo group. The Wald test was also used to examine if within-person change in the proportion of urinary As metabolites differed between the 400FA, 800FA, and creatine + 400FA treatment groups. To aid interpretation, group differences in the mean within-person changes were derived from relevant model parameters.
The rebound in urinary As metabolites after cessation of FA supplementation during the second phase (wk 12-24) was similarly assessed through the use of linear models with repeated measures applied to the 400FA and 800FA groups. The models that described the data well included parameters for treatment 2 400FA: n = 131. 3 Placebo: n = 89; 400FA: n = 130; 800FA: n = 126; creatine: n = 92; creatine + 400FA: n = 95. 4 Placebo: n = 89; 400FA: n = 130; 800FA: n = 128; not measured for creatine and creatine + 400 FA groups. 5 Creatine: n = 93.
groups, time (wk 0, 12, and 24), continuation status of FA supplementation, and 2-way interactions of group-by-FA continuation, group-by-time, and time-by-FA continuation. Time-by-FA continuation interactions indicate differences in mean withinsubject change in percentage As metabolites between groups that continued and discontinued FA supplementation. From the model parameters, we derived the differences between FA groups in the mean within-person changes over periods of interest to describe the rebound effect. Analyses were performed with the use of SAS 9.4 (SAS Institute, Cary, NC) or R 3.2.2 (R Foundation, Vienna, Austria) (32).
RESULTS
Baseline characteristics by treatment group are presented in Table 1 . Participants ranged in age from 24 to 55 y, and approximately half (51.5%) were men. There were no statistically significant differences between treatment groups in age; sex; BMI; history of betel nut use or smoking; land ownership; water, blood, and urinary As concentrations; urinary As species concentrations; or nutritional status, including RBC and plasma folate, folate status, plasma B-12, B-12 status, plasma homocysteine, and hyperhomocysteinemia. Urinary creatinine was significantly correlated with %InAs at baseline (Spearman correlation coefficient r s = −0.28, P < 0.001) and %DMAs (r s = 0.13, P = 0.002). There were no significant treatment group differences in baseline percentage urinary As metabolites (Kruskall-Wallis test %InAs P = 0.136; %MMAs P = 0.578; %DMAs P = 0.235).
After treatment began, there was an initial decrease in total urinary As among all treatment groups as a result of the use of As removal filters. There was also a notable initial decrease in SG and urinary creatinine concentrations, suggesting that participants were drinking more water after receiving the filters. We consider this to be a "new toy effect," however, as total urinary As concentration, SG, and urinary creatinine concentration gradually increased after the first week, indicating that participants' water intake returned to normal and that they used the water filters less frequently as the study progressed. After adjusting for SG, the trend in total urinary As remained (Figure 3) . Use of the water filters and total urinary As concentrations during this trial have been detailed by Sanchez et al. (26) . At wk 12, the mean total urinary As concentration was 15% lower than baseline among all participants (P < 0.0001). At a revisit conducted 1 y after the study was completed, the majority of participants reported decreasing or stopping use of the filters because the water was filtered more slowly over time. 
FIGURE 3
Total urinary As, SG, and total urinary As adjusted for SG. Placebo (n = 90); 400FA (n = 133); 800FA (n = 129); creatine (n = 94); creatine + 400FA (n = 96). 400FA, 400 μg FA per day treatment group; 800FA, 800 μg FA per day treatment group; creatine, 3 g creatine per day treatment group; creatine + 400FA, 3 g creatine and 400 μg FA per day treatment group; FA, folic acid; SG, specific gravity.
Treatment effects during the first phase
As we have previously reported, FA supplementation increased plasma and RBC folate (20) and decreased homocysteine (33) at wk 12 ( Table 2) . Table 2 and Figure 4 present the mean percentage urinary As metabolites at baseline and wk 1, 6, and 12. Overall treatment group differences in ln(%InAs) were significant at wk 1, 6, and 12; differences in %MMAs and %DMAs were significant at wk 6 and 12 (ANOVA P < 0.05). At wk 1, the 800FA group had significantly lower ln(%InAs) than the placebo group (Dunnett's t test P < 0.05). At wk 6 and 12, the 3 groups receiving FA supplements had significantly lower %InAs and %MMAs, and higher %DMAs compared with the placebo group (Dunnett's t test P < 0.05). The proportions of urinary InAs, MMAs, and DMAs were not significantly different between the creatine and placebo groups at any followup (Dunnett's t test P > 0.05).
Treatment group differences in within-person change in urinary As metabolites between baseline and wk 1, 6, and 12 were examined with the use of available data from the 542 subjects, which included 1966 observations (wk 0: n = 542; wk 1: n = 456; wk 6: n = 461; wk 12: n = 507). The treatment effects on within-person changes in As metabolite proportions over the first 6 wk were similar to the effects on the changes over 12 wk, indicated by a linear model with 20 parameters where the time variable had 4 categories (wk 0, wk 1, wk 6, and wk 12). Therefore, data were described by a parsimonious model with 3 categories for the time variable (wk 0, wk 1, and wk 6 and 12). Table 3 displays results from the parsimonious model. The observed geometric mean of %InAs and means of %MMAs and %DMAs were similar to the modelbased estimates (Figure 4) , indicating that the model fit the data well. There was a significantly greater mean decrease in mean ln(%InAs) from baseline to wk 12 in the 400FA, 800FA, and 10 13.0 ± 5.9 9.8 ± 3.3* 9.6 ± 4.1* 11.5 ± 4.2 9.7 ± 2.8* <0.001
creatine + 400FA groups than in the placebo group (P < 0.05). There were no significant group differences in the mean change in ln(%InAs) between the creatine and placebo groups. The mean decrease in %MMAs at wk 1 and wk 6 and 12 was significantly greater than the placebo group for all treatment groups (P < 0.05) except for the creatine + 400FA group at wk 1. The mean within-person increase in %DMAs was significantly larger in the 800FA group than in the placebo group at wk 1; and was significantly larger in the 400FA, 800FA, and creatine + 400FA groups than in the placebo group at wk 6 and 12 (P < 0.05). The mean change in %DMAs at wk 6 and 12 was not significantly different between the creatine group and the placebo group. Using linear models with repeated measures, we also examined if within-person changes in the proportion of urinary As metabolites between baseline and wk 1, 6, and 12 differed between the 400FA, 800FA, and creatine + 400FA treatment groups. Changes in the proportion of all metabolites from baseline to wk 1 or wk 6 and 12 did not differ between the 400FA and 800FA groups, or between the 400FA and creatine + 400FA groups, with the exception that the decrease in %MMAs from baseline to wk 6 and 12 was larger in the 800FA group than in the 400FA group (P = 0.034).
Treatment effects in the second phase
Proportions of urinary As metabolites after FA cessation in the 400FA and 800FA groups are shown in Table 4 . At wk 24, mean ln(%InAs) and %DMAs in both FA dose groups that discontinued FA supplementation were not significantly different than baseline levels. From baseline to wk 24, there was a significantly greater mean decrease in %InAs and increase in %DMAs in both groups that continued FA supplementation compared with groups that discontinued supplementation (%InAs: timeby-FA continuation interaction P = 0.028; %DMAs: time-by-FA continuation interaction P = 0.0005). A similar pattern was observed in %MMAs with a significant difference at wk 24 between groups that discontinued and continued FA supplementation (time-by-FA continuation P = 0.048); however, %MMAs at wk 24 remained lower than baseline in the 400FA group that discontinued FA supplementation (P = 0.018).
DISCUSSION
The purpose of this RCT was to investigate the effect of FA and creatine supplementation on As methylation among a population of mixed folate-deficient and -sufficient individuals. 
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Mean %DMAs
FIGURE 4
Percentage urinary As metabolites at wk 0-12. Symbols represent raw means, and lines represent the predicted means from a linear model with repeated measures of urinary As metabolites. As shown in Table 2 , ln(%InAs) was significantly different between treatment groups at wk 1, 6, and 12; %MMAs and %DMAs were significantly different between treatment groups at wk 6 and 12 (ANOVA P < 0.001). The 800FA group had significantly lower ln(%InAs) at wk 1 than the placebo group (Dunnett's t test P < 0.05). The 3 groups receiving FA supplements had significantly lower %InAs and %MMAs, and higher %DMAs than the placebo group at wk 6 and 12 (Dunnett's t test P < 0.05). The proportions of urinary As metabolites were not significantly different between the creatine and placebo groups at any follow-up (Dunnett's t test P < 0.05). Placebo (n = 90); 400FA (n = 133); 800FA (n = 129); creatine (n = 94); creatine + 400FA (n = 96). 400FA, 400 μg FA per day treatment group; 800FA, 800 μg FA per day treatment group; creatine, 3 g creatine per day treatment group; creatine + 400FA, 3 g creatine and 400 μg FA per day treatment group; DMAs, dimethyl-arsenical species; FA, folic acid; InAs, inorganic arsenic; MMAs, monomethyl-arsenical species.
FA supplementation significantly increased As methylation; at wk 6 and 12, there was a greater decrease in ln(%InAs) and %MMAs and increase in %DMAs among groups that had received 400 or 800 μg FA per day compared with placebo. The higher dose of FA had a greater effect on As methylation, as the decrease in %MMAs from baseline to wk 6 and 12 was larger in the 800FA group than in the 400FA group. Previously published findings from this trial demonstrated that supplementation of 800 μg FA per day, but not 400 μg FA per day, decreased total blood As concentrations to a significantly greater extent than placebo (20) .
These findings are in agreement with our previous 12-wk RCT of the effects of supplementation with 400 μg FA per day to folate-deficient adults in Bangladesh who did not receive As removal filters (16) . In that study, FA supplementation resulted in significant decreases in ln(%InAs) and %MMAs, and increases in %DMAs in urine as compared with placebo. Arsenic methylation capacity was also assessed by the primary methylation index (PMI, calculated as MMAs/InAs) and secondary methylation index (SMI, calculated as DMAs/MMAs). Similar to the current study, effects were observed as early as 1 wk after treatment began; SMI significantly increased by the wk 1 follow-up in the group receiving FA compared with placebo.
Results from this trial provide evidence supporting the hypothesis that FA supplementation increases As methylation capacity, presumably by enhancing the synthesis of SAM, the methyl donor for As methylation, through provision of folate-derived methyl groups for one-carbon metabolism. Notably, effects of 1 Treatment group differences in mean changes were derived from relevant group-by-time interaction parameters of the linear models with repeated measures where time was a variable with 3 categories (wk 0, wk 1, wk 6 and 12). 400FA, 400 μg FA per day treatment group; 800FA, 800 μg FA per day treatment group; creatine, 3 g creatine per day treatment group; creatine + 400FA, 3 g creatine and 400 μg FA per day treatment group; DMAs, dimethyl-arsenical species; FA, folic acid; InAs, inorganic arsenic; MMAs, monomethyl-arsenical species.
* P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001 for group-by-time interaction parameters of the linear models with repeated measures.
FA supplementation were observed in a population that was predominantly folate sufficient (plasma folate ≥ 9 nmol/L in 80.2% of total participants). Although the study was powered to detect differences in the full sample of both folate-deficient and -sufficient individuals, stratified analyses suggest that results were not driven by changes among participants who were folatedeficient at baseline. At wk 12, the mean changes in percentage As metabolites were similar between the folate-deficient andsufficient strata in the groups receiving FA supplementation. In the 400FA treatment group, the mean changes in As metabolite proportions for participants with baseline deficient (n = 31) and sufficient folate status (n = 102) were, respectively: ln(%InAs): −0.08, −0.04; %MMAs: −1.91, −1.98; %DMAs: 2.67, 2.25. Similarly, in the 800FA treatment group, the mean changes for folate-deficient (n = 23) and -sufficient participants (n = 106) were, respectively: ln(%InAs): −0.07, −0.13; %MMAs: −1.96, −2.26; %DMAs: 2.83, 3.72.
The results suggest that percentage of urinary As metabolites returned to baseline levels 12 wk after cessation of FA supplementation, as mean %InAs and %DMAs were not significantly different than baseline levels in those groups that discontinued FA supplementation. However, as previously reported, although blood As concentrations did increase after discontinuation of FA supplementation, the increase did not achieve statistical significance (20) . In light of results regarding urinary As metabolites, the follow-up period may not have been long enough to observe a complete rebound in blood As after cessation of FA supplementation.
Creatine supplementation moderately influenced the proportion of As metabolites in urine. Although no significant differences were observed in the change in ln(%InAs) and %DMAs between the creatine and placebo groups at any time point, the decrease in %MMAs was significantly greater at wk 1 and wk 6 and 12 in the creatine group than in the placebo group. In previously published results, creatine supplementation did not affect total blood As (20) . Our a priori hypothesis was that creatine supplementation would increase As methylation capacity by decreasing creatine biosynthesis, a major consumer of SAM methyl groups (14) , and multiple studies have reported strong positive cross-sectional associations between urinary creatinine and As methylation capacity (15, 18, (21) (22) (23) (24) ). In the current study, we also observed significant correlations between urinary creatinine and %InAs and %DMAs. As we reported previously, supplementation of 3 g creatine per day did decrease creatine biosynthesis in this study population; concentrations of plasma guanidinoacetate, a precursor to creatine in the creatine biosynthetic pathway, significantly decreased with creatine supplementation, indicating a reduction in creatine biosynthesis (33) . The current findings lend support to the hypothesis that a decrease in creatine biosynthesis achieved through creatine supplementation may influence As methylation; however, the magnitude of the effects may be somewhat tempered by long-range allosteric regulation of 1-carbon metabolism that regulates intracellular SAM concentrations. For example, SAM inhibits methylenetetrahydrofolate reductase (MTHFR) (34) , thereby decreasing synthesis of 5-MTHF and releasing 5-MTHF mediated inhibition of glycine N-methyltransferase (GNMT) activity (35) . GNMT serves as a major regulator of SAM concentrations through utilization of SAM for the nonessential conversion of glycine to sarcosine (35, 36) . In an in silico experiment that used a mathematic model of one-carbon metabolism, when creatine synthesis is set to 0, flux through GNMT increases by 30%. And, SAM concentrations are further modulated through increased flux through the transsulfuration pathway because SAM stimulates cystathionine ß-synthase (37) . Additional unknown mechanisms may contribute to the strong cross-sectional associations between urinary creatinine and As methylation capacity. For example, it is possible that urinary creatinine is somehow related to renal tubular reabsorption of InAs, a topic that is relatively understudied in the scientific literature.
As noted earlier, this study was powered to test the effects of FA and creatine supplementation on a population of mixed folate-deficient and -sufficient individuals. Significant effects were observed among folate-sufficient participants receiving FA supplementation. In addition, the trial focused on the effects of increasing the recruitment of methyl groups to enhance onecarbon metabolism. However, As methylation capacity may also be altered by increasing the availability of other methyl donors involved in one-carbon metabolism (38) . Further research is needed to explore the impact of cosupplementation of FA with other methyl donors, such as choline and betaine, and other micronutrients related to one-carbon metabolism, such as vitamins B-12, B-2, and B-6. Furthermore, treatment effects may differ by baseline nutritional status of these micronutrients.
The study limitations include poor compliance with water filter use over time and the possibility that some urine samples were diluted with water. However, it is unlikely that either of these factors differed between treatment groups owing to randomization, and therefore they are not expected to influence the study's conclusions.
In conclusion, the importance of nutritional factors in modifying As metabolism and toxicity has emerged over the past 20 y (39), as well as the potential use of nutritional supplements to mitigate the health effects of chronic As exposure (40) . Remediation of As exposure is the most important approach to limiting health effects (3); however, removal of As from drinking water may not be immediately feasible in all realworld situations and exposure to unsafe concentrations of As in drinking water persists in many regions of the world (1). Furthermore, adverse health outcomes associated with chronic As exposure persist after exposure has ended (41, 42) . Additional approaches to lower blood As, increase As methylation, and potentially reduce As toxicity are needed. In this trial, FA supplementation significantly increased As methylation capacity, resulting in an increased proportion of urinary DMAs, the least toxic and most readily excreted As metabolite. A significant change in the proportions of InAs and DMAs was not observed in the creatine group, although findings suggest that creatine supplementation decreased %MMAs to a lesser extent than FA. Although these findings are informative, further research is needed to fully understand the strong cross-sectional relations previously observed between urinary creatinine and arsenic methylation (15, 21, 22, 24) .
Nutritional interventions may conceivably reduce long-term health risks of As exposure. For example, folate deficiency has been associated with the subsequent development of skin lesions (43) . FA fortification of grains has been shown to dramatically decrease the prevalence of folate deficiency (44, 45) and has been mandated in 87 countries (46); however, Bangladesh is not among them. Countries with endemic As exposure, such as Bangladesh, may benefit from FA fortification to reduce folate deficiency in general, and as a cost-effective method of partly reducing As toxicity as one component of comprehensive As mitigation programs.
